Growth

Bringing TPG’s scale and expertise to drive Innovation in life sciences

TPG Life Sciences Innovations (LSI) seeks to partner with companies developing disruptive science, technologies and business models to meaningfully improve outcomes in patients with significant unmet medical needs. Our investment team leverages deep scientific, clinical and operational expertise, as well as our investment experience across multiple therapeutic areas and modalities. We invest thematically, with a focus on areas such as oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, as well as commercial stage medical devices and tech-enabled services.

Built on a track record of successfully investing in and supporting cutting-edge life sciences

LSI builds on TPG’s market leading healthcare franchise with over $30 billion invested across the broader global healthcare ecosystem since 2003. We are well versed with structuring the right deal for life sciences companies with varying maturities and capital needs.

Our approach to inflection capital advances breakthrough technologies to clinical proof-of-concept, which we believe is the key value inflection in delivering demonstrable benefits to patients. Our investing strategy is hyper-focused on disruptive science and businesses that create real clinical impact. As the pace of innovation in the life sciences sector accelerates, LSI is well positioned to partner with companies and entrepreneurs to support them from company creation through clinical development to commercial stages. This is achieved by bringing the firm’s decades of business-building experience, operating capabilities, and industry relationships to drive enduring growth and success.